Business Context and Reporting Period
This Form 8-K Current Report was filed by AIT Therapeutics, Inc. (trading symbol: AITB) on June 7, 2019, covering events occurring on June 3, 2019. The company is an emerging growth company incorporated in Delaware. The filing primarily reports the completion of a private placement equity offering.
Key Financial Metrics
The filing details a capital raise event rather than operational financial performance metrics such as revenue or operating margins.
- Shares Issued: 1,592,127 shares of common stock.
- Price Per Share: $5.00.
- Total Proceeds: Approximately $7,960,635 (calculated as 1,592,127 shares multiplied by $5.00).
- Transaction Type: Direct sale to accredited investors without an underwriter or placement agent.
Material Changes
The material change reported is the increase in the company's equity capital and outstanding share count resulting from the closed Offering on June 3, 2019. The transaction was executed under Section 4(a)(2) of the Securities Act and Rule 506, exempting it from registration as a public offering.
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance, management commentary on future operations, or a detailed risk factor analysis beyond the standard legal disclosures associated with unregistered securities sales. The company noted that the securities were acquired for investment purposes only and not for distribution. A press release describing the offering was issued on June 4, 2019.
Investor Verification Checklist
- Verify the exact use of proceeds from the $7.96 million offering in subsequent filings (e.g., 10-Q or 10-K).
- Confirm the updated total number of outstanding shares post-offering to assess dilution impact.
- Review the Form of Subscription Agreement (Exhibit 10.1) for any specific covenants or restrictions placed on the investors.
- Check for any subsequent press releases or filings detailing how the capital will be deployed to advance the company's therapeutic pipeline.